Related Experiment Video
Updated: Jun 24, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Are We Using Ezetimibe As Much As We Should?
Antonis A Manolis1, Theodora A Manolis2, Dimitri P Mikhailidis3
1Cardiology Department, Evagelismos Hospital, Athens, Greece.
Insights
Ezetimibe is an effective and affordable lipid-lowering therapy, often used with statins to reach low-density lipoprotein cholesterol (LDL-C) goals. It improves cardiovascular outcomes and is a good alternative for statin-intolerant patients.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Many patients with atherosclerotic cardiovascular disease (CVD) do not achieve target low-density lipoprotein cholesterol (LDL-C) levels with statin therapy alone.
- Statin-associated adverse effects limit their widespread use and optimal management of CVD.
- Non-statin lipid-lowering therapies are underutilized despite the unmet need for effective CVD risk reduction.
Purpose of the Study:
- To provide a comprehensive review of ezetimibe's effects on lipid lowering, cardiovascular (CV) event reduction, and outcome improvement.
- To evaluate ezetimibe as a monotherapy or in combination with statins for managing dyslipidemia and reducing CVD risk.
- To assess ezetimibe's role as an alternative treatment for patients with statin intolerance.
Main Methods:
- Review of clinical trial data and outcomes studies on ezetimibe.
- Analysis of ezetimibe's efficacy in monotherapy and combination therapy with statins.
- Evaluation of ezetimibe's safety and tolerability profile compared to other lipid-lowering agents.
Main Results:
- Ezetimibe, as oral monotherapy or combined with statins, is an effective and affordable option for achieving LDL-C goals.
- Combination therapy with ezetimibe and statins enhances lipid-lowering effects (approx. 20%) and allows for lower statin doses, reducing side effects.
- Ezetimibe demonstrates efficacy in reducing CVD risk and events, supported by cardiovascular outcomes data.
Conclusions:
- Ezetimibe is a convenient and effective first-line add-on therapy to statins for achieving LDL-C targets.
- It offers an excellent safety and tolerability profile, enhancing lipid-lowering effects and potentially mitigating statin-related side effects.
- Ezetimibe serves as a valuable alternative treatment option for patients unable to tolerate statins, contributing to improved CVD management.
Abstract:
Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) are not optimally managed, and do not attain target low-density lipoprotein cholesterol (LDL-C) concentrations, despite statin treatment. Statins have been the mainstay of hypolipidemic therapies; however, they are plagued by adverse effects, which have partly hindered their more widespread use. Ezetimibe is often the first added mode of treatment to attain LDL-C goals as it is efficacious and also allows the use of a smaller dose of statin, while the need for more expensive therapies is obviated. We herein provide a comprehensive review of the effects of ezetimibe in lipid lowering and reducing CV events and improving outcomes. Of the hypolipidemic therapies, oral ezetimibe, in contrast to newer agents, is the most convenient and/or affordable regimen to be utilized as mono- or combined therapy supported by data from CV outcomes studies attesting to its efficacy in reducing CVD risk and events. When combined with a statin, the statin dose could be lower, thus curtailing side-effects, while the hypolipidemic effect is enhanced (by ~20%) as the percentage of patients with target level LDL-C (<70 mg/dL) is higher with combined treatment versus a high-intensity statin. Ezetimibe could also serve as an alternative treatment in cases of statin intolerance. In conclusion, ezetimibe has an excellent safety/tolerability profile; it is the first added treatment to a statin that can attain LDL-C targets. In the combined therapy, the hypolipidemic effect is enhanced while the dose of statin could be lower, thus limiting the occurrence of side-effects. Ezetimibe could also serve as an alternative mode of treatment in cases of statin intolerance.
More Related Videos
06:00Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...